All Press Releases

»All Press Releases
29 08, 2019

Eiger BioPharmaceuticals to Participate in September Conferences

2019-08-29T20:16:25+00:00

Eiger BioPharmaceuticals to Participate in September Conferences PALO ALTO, Calif. – August 29, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in the following upcoming investor conferences in September: Baird 2019 Global Healthcare Conference at the [...]

Eiger BioPharmaceuticals to Participate in September Conferences2019-08-29T20:16:25+00:00
20 08, 2019

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection

2019-08-20T12:48:11+00:00

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection Fourth Eiger Program Granted Breakthrough Therapy Designation PALO ALTO, Calif., August 20, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and [...]

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection2019-08-20T12:48:11+00:00
6 08, 2019

Eiger BioPharmaceuticals to Participate in Investor Conferences in August

2019-08-06T18:37:29+00:00

Eiger BioPharmaceuticals to Participate in Investor Conferences in August PALO ALTO, Calif. – August 5, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in August. BTIG Biotechnology Conference at St. Regis [...]

Eiger BioPharmaceuticals to Participate in Investor Conferences in August2019-08-06T18:37:29+00:00
17 06, 2019

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)

2019-06-17T20:57:19+00:00

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH) Third Eiger Pipeline Program Granted Breakthrough Therapy Designation PALO ALTO, Calif., June 17, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food [...]

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)2019-06-17T20:57:19+00:00
10 06, 2019

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs

2019-06-10T13:59:43+00:00

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs PALO ALTO, Calif., June 10, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, today announced the appointment of Mark Mannebach, PhD, RPh as Vice President [...]

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs2019-06-10T13:59:43+00:00
5 06, 2019

Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development

2019-06-05T15:04:41+00:00

Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development PALO ALTO, Calif., June 5, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA as Vice President of Global [...]

Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development2019-06-05T15:04:41+00:00
30 05, 2019

Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference

2019-05-30T14:39:10+00:00

Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference PALO ALTO, Calif., May 30, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the Jefferies 2019 Global Healthcare [...]

Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference2019-05-30T14:39:10+00:00
17 05, 2019

Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer

2019-05-17T20:53:43+00:00

Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer PALO ALTO, Calif., May 17, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Apelian will step down as the Company’s Chief Operating Officer and Executive Medical [...]

Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer2019-05-17T20:53:43+00:00
9 05, 2019

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

2019-05-09T20:50:39+00:00

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update First-Ever Phase 3 HDV International “D-LIVR” Study UnderwayNDA and MAA filings for Progeria & Progeroid Laminopathies planned in 2019Strong Balance Sheet with Recent Financing CompletedPALO ALTO, Calif., May 9, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted [...]

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update2019-05-09T20:50:39+00:00
30 04, 2019

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 2019

2019-04-30T13:24:14+00:00

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 2019 PALO ALTO, Calif., April 30, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will participate and present a corporate update at the ChinaBio® Partnering [...]

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 20192019-04-30T13:24:14+00:00